Cure My Disease

Don't miss your cure!

 Log in / Sign up

New kidney disease drug under watch in Real-World patients

NCT ID NCT07156149

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is monitoring the safety and effectiveness of Fabhalta capsules in patients with C3 glomerulopathy, a rare kidney disease. It will follow about 50 patients in real-world clinical practice for up to a year. The main goal is to track infections and other side effects, while also checking if the drug helps protect kidney function by measuring protein in urine and kidney filtration rates.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Novartis Investigative Site

    RECRUITING

    Nagoya, Aichi-ken, 466-8650, Japan

  • Novartis Investigative Site

    RECRUITING

    Sapporo, Hokkaido, 0040041, Japan

  • Novartis Investigative Site

    RECRUITING

    Sapporo, Hokkaido, 060-8604, Japan

  • Novartis Investigative Site

    RECRUITING

    Komatsu, Ishikawa-ken, 923-0961, Japan

  • Novartis Investigative Site

    RECRUITING

    Tsu, Mie-ken, 514-8507, Japan

  • Novartis Investigative Site

    RECRUITING

    Shimajiri-Gun, Okinawa, 901-1303, Japan

  • Novartis Investigative Site

    RECRUITING

    Takatsuki, Osaka, 5698686, Japan

  • Novartis Investigative Site

    RECRUITING

    Kusatsu, Shiga, 525-8585, Japan

  • Novartis Investigative Site

    RECRUITING

    Ohtsu, Shiga, 5202192, Japan

  • Novartis Investigative Site

    RECRUITING

    Shimotsuga Gun, Tochigi, 321-0293, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo-ku, Tokyo, 1138519, Japan

  • Novartis Investigative Site

    RECRUITING

    Fuchū, Tokyo, 1838561, Japan

  • Novartis Investigative Site

    RECRUITING

    Shinjuku Ku, Tokyo, 1628666, Japan

  • Novartis Investigative Site

    RECRUITING

    Yosa, Yosa, 629-2261, Japan

  • Novartis Investigative Site

    RECRUITING

    Wakayama, 640-8558, Japan

Conditions

Explore the condition pages connected to this study.

C3 GLOMERULOPATHY